强化降脂治疗对非ST段抬高急性冠状动脉综合征患者血清炎性因子的影响  

Effect of intensive lipid lowering therapy on the serum inflammatory factors in conservatively treated non ST elevation acute coronary syndrome

作　　者：刘京锋[1] 汪钰[1] 王学东[1] 

机构地区：[1]北京市和平里医院CCU病房,100013

出　　处：《心肺血管病杂志》2016年第2期101-105,共5页Journal of Cardiovascular and Pulmonary Diseases

摘　　要：目的:探讨强化降脂治疗对非ST段抬高型急性冠状动脉综合征(NSTE-ACS)保守治疗患者的预后及血清炎性因子的影响。方法:将79例NSTE-ACS保守治疗患者随机分为两组,对照组(瑞舒伐他汀10mg组)39例,强化降脂组(瑞舒伐他汀20mg组)40例,于30d的治疗期前后检测两组血清高敏C反应蛋白(hs-CRP)、可溶性凝集素样氧化低密度脂蛋白受体-1(s LOX-1)变化。随访60d,观察心血管事件和不良事件发生率。结果:与治疗前相比,两组的hs-CRP、s LOX-1均有所下降(P<0.01),强化降脂组s LOX-1的下降程度较对照组明显(P<0.01),而hs-CRP两组间差异无统计学意义(P=0.053)。随访发现,强化降脂组心血管事件发生例数少于对照组,两组均未见明显肝功、肾功异常。结论:对于NSTE-ACS保守治疗患者,强化降脂能明显降低血清s LOX-1水平,减轻心肌和血管内皮炎症反应。Objective： To investigate the efficacy of intensive lipid lowering therapy on the prognosis and serum inflammatory factors in patients with non ST elevation acute coronary syndrome（ NSTE-ACS）.Methods： 79 patients with NSTE-ACS were divided into two groups： control group（ rosuvastatin 10 mg group）with 39 cases,intensive lipid-lowering group（ rosuvastatin 20 mg group） with 40 cases. Before and 30 days after the treatment,blood samples in each group were collected from cubital vein,and serum high sensitive C reactive protein（ hs-CRP）,soluble lectin like oxidized low density lipoprotein receptor 1（ s LOX-1） were measured by enzyme linked immunosorbent assay. The incidence of cardiovascular events and adverse events were observed as well. Results： Compared with baseline,hs-CRP and s LOX-1 significantly declined in both groups（ P〈0. 01）. Intensive lipid-lowering group displayed a more remarkable decrease of s LOX-1 than the control group（ P〈0. 01）,while the decrease of hs-CRP did not differ between the two groups（ P = 0. 053）. Incidence of cardiovascular events is lower in intensive lipid-lowering group than the control group. Compared with baseline,neither groups showed significant abnormal liver function and kidney function. Conclusion： For patients with NSTE-ACS,enhanced lipid lowering can significantly reduce serum s LOX-1 levels,suppress myocardial and vascular endothelial inflammatory reaction.

关 键 词：非ST段抬高型急性冠状动脉综合征 强化降脂 瑞舒伐他汀 炎性因子 

分 类 号：R54[医药卫生—心血管疾病]